Pharmaceutical Executive
The Promise Of Translational Medicine
Pharmaceutical Executive-02-01-2011
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
Pharmaceutical Executive
Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Report: Richard Pazdur Out as Director of CDER
4
Patients Avoid Care as Healthcare Costs Rise: Report
5
